^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LK101

    i
    Other names: LK101, LK-Neo DC
    Associations

    News

    Trials
    Company:
    Likang Life Sci
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4d
    LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase classification: P1 --> P1/2 | N=40 --> 60 | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> May 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • LK101
    over2years
    LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • LK101